Hepatic Cirrhosis
Conditions
Interventions
Observations group:None
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Able to understand and voluntarily sign the informed consent form, and can complete the trial according to the protocol requirements;2. Aged 18-75 years, regardless of gender;3. Clinically diagnosed patients with liver cirrhosis (without known heart disease);4. Subjects with no contraindications for MRI and history of allergy to gadolinium contrast agents;5. Laboratory indicators must meet the following: (1) Blood routine 1) WBC >=4.0×10?/L or neutrophils >=1.5×10?/L; 2) PLT >=100×10?/L; 3) Hb >=90 g/L; 4) PT or APTT <=1.5×ULN (upper limit of normal values). (2) Liver and kidney function 1) T-Bil <=1.5×ULN; 2) ALT/AST <=2.5×ULN; 3) ALP <=2.5×ULN; 4) BUN <=1.5×ULN; 5) SCr <=1.5×ULN; 6) Child-Pugh classification A to C; 7) NT-proBNP <=300 pg/mL. (3) Other routine tests within normal range or considered acceptable by the investigator;6. Females must use effective contraceptive measures during the study and for 6 months after the study ends (effective contraceptive measures refer to sterilization, intrauterine hormone devices, condoms, contraceptive pills/devices, abstinence, or partners with vasectomies, etc.); males must agree to use contraceptive measures during the study and for 6 months after the study ends.
Exclusion criteria
Exclusion criteria: 1.With combined hypertension, diabetes, coronary artery disease, or malignancy; 2.Having recently undergone cardiac surgery or interventional treatment; 3.With severe systemic or local infections, or other severe concomitant diseases; 4.With severely abnormal liver or kidney function; 5.Who refuse to participate in this clinical study; 6.With a history of allergy to any component of the imaging agent, including antibodies, or with an allergic constitution; 7.Male and female subjects of childbearing potential who cannot take effective contraceptive measures; 8.Women in the preconception, pregnant, or breastfeeding period; 9.Unable to undergo PET/CT scanning; 10.Any other subjects deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum standardized uptake value; | — |
Countries
China
Contacts
Public ContactYangyang Wang
The Affiliated Hospital of Qingdao University
Outcome results
None listed